ArticleJournal of cannabis research2026
Astrocytic GPR55 receptors promote glycolysis.
Article in Journal of cannabis research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neurotoxicity of Synthetic Cannabinoid Receptor Agonist Cumyl-PINACA: An In Vitro Study on Rat Cortical Neurons and Astrocytes.Pharmaceuticals (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundThe endocannabinoid system is closely associated with systemic and cellular energy metabolism in mammals. We previously demonstrated that the cannabinoid receptors CB1 and CB2 play important roles in cerebral glucose metabolism. GPR55, a paracannabinoid receptor, has been implicated in systemic metabolic regulation and in diseases such as intractable epilepsy, diabetes, and cancer. In the present study, we investigated whether GPR55 also influences brain glucose metabolism.
methodsAcute hippocampal and cortical slices and primary astrocytic cultures from C57BL/6 mice and Wistar rats were used. Quantitative polymerase chain reaction (qPCR) was used to assess Cnr1 and Gpr55 gene expression levels, and [³H]deoxyglucose/[¹⁴C]-U-glucose uptake assays, high-resolution respirometry using the Oroboros O2k system, and proton nuclear magnetic resonance ([¹H]-NMR) spectroscopy were employed to assess metabolic activity upon receptor activation.
resultsqPCR analysis revealed that Cnr1 mRNA dominated in neurons, whereas Gpr55 was predominantly expressed in primary astrocytes. Δ⁹-Tetrahydrocannabinol (Δ⁹-THC), the GPR55-selective synthetic agonist O-1602, the endogenous GPR55 agonists, L-α-lysophosphatidylinositol (LPI) and palmitoylethanolamide (PEA), together with the mixed CB1 receptor antagonist/GPR55 agonist AM251, invariably and significantly stimulated glucose uptake and metabolism in brain preparations at nanomolar concentrations ex vivo. The GPR55-selective antagonist CID16020046 (1 µM) abolished the effects of the GPR55 agonists, as did pretreatment with the cytosolic Ca2+ chelator BAPTA-AM (30 µM). While LPI did not alter oxidative metabolism in either astrocytes or neurons, it selectively stimulated glycolysis and lactate release in astrocytes.
conclusionsOur findings reveal a novel role for GPR55 in astrocytes. By enhancing glycolytic activity in these cells, GPR55 is likely poised to support, even if indirectly, the energy demands of synaptic transmission.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.